We use our unique microRNA-based biomarkers to personalize cancer treatment and drug development.

miradx gene

We partner with cancer clinics and pharmaceutical companies



MiraDx is creating biomarker panels to predict both toxicity (immune-related adverse events (iRAEs)) as well as response to the developing immunotherapies. Their first test predicts iRAEs to anti-PD1/PDL1 therapy across all cancer types. So, patients with any type of cancer who are being considered for this therapy are eligible for testing. More about ImuDx testing

Recent data now indicates that changing estrogen levels, specifically estrogen withdrawal, can trigger cancer in women with the KRAS-variant. Knowing a woman’s KRAS-variant status is an additional piece of critically important information to help direct decisions for estrogen management, as well as primary and secondary cancer screening. More about KRAS-variant testing

MiraDx has a program to confirm a diagnosis of Ataxia Telangiectasia in children, based on work from the Gatti laboratory spanning over 40 years. More about AT Testing



MiraDx is developing panels of biomarkers to apply before radiation therapy treatment to identify patients who have different sensitivities and responses to radiation therapy to make strides to personalize radiotherapy. More about our research on Radiogenomics

Learn about PROSTOXTM here, a radiogenomics assay that can help prostate cancer patients avoid toxicity from radiation therapy.

Featured Study

KRAS-variant overall survival

A KRAS-variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.

The KRAS-variant predicts significantly worse overall survival for post-menopausal ovarian cancer patients over 52 years of age. Overall survival for ovarian cancer patients with and without the KRAS-variant are compared using Kaplan Meier analysis. Outcome is significantly worse for KRAS-variant positive EOC patients over 52 years of age by log-rank test. This poor outcome is due to Platinum resistance for KRAS-variant patients which has been found across many cancer types.

Interested in partnering with us?